Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins
Executive Summary
MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.
You may also be interested in...
Immunocore To Tap Into HTA Advice To Ensure IMCgp100 Success
British immunotherapy specialist Immunocore plans to make full use of the scientific advice European HTAs are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's Adaptive Pathways pilot program.
MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers
The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.
MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers
The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.